Summary by Futu AI
Adimab, LLC, a Delaware-based limited liability company, has filed an amendment to its Schedule 13D with the U.S. Securities and Exchange Commission (SEC), reporting a significant transaction involving shares of Invivyd, Inc. The amendment, dated January 19, 2024, indicates that Adimab, LLC has sold 5,000,000 shares of Invivyd's common stock. The sale was executed under Rule 144 at a price of $3.95 per share. Following the sale, Adimab, LLC still beneficially owns 21,687,906 shares, representing 19.7% of Invivyd's class of common stock. This ownership percentage is based on the 110,114,960 shares of common stock outstanding as reported in Invivyd's Quarterly Report for the quarter ended September 30, 2023. The amendment also notes that the company, formerly known as Adagio Therapeutics, Inc., officially changed its name to Invivyd, Inc. on September 13, 2022, following the filing of a certificate of amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware. No other transactions in Invivyd's common stock were reported by Adimab, LLC or related persons in the past 60 days.
